Simcere has signed a strategic partnership with Sun Yat-Sen University Cancer Center in China. Under the agreement, Simcere and Sun Yat-Sen University Cancer Center will cooperate on researching and developing anti-cancer drugs, as well as conducting a joint training program to develop personnel in advanced R&D.
Jinsheng Ren, chairman and CEO of Simcere, said: We are delighted to enter into a strategic partnership with Sun Yat-Sen University Cancer Center. I am confident that this cooperation will enhance Simcere’s R&D capabilities and contribute to the future development of innovative cancer drugs in China.
Simcere is a manufacturer and supplier of branded generic pharmaceuticals, and producer of the patented anti-cancer drug – Endu, in the Chinese market.